{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:34:55Z","timestamp":1792121695766,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clml.2020.10.002","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T21:50:50Z","timestamp":1603489850000},"page":"e160-e175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-1589","authenticated-orcid":false,"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moushmi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2782-2437","authenticated-orcid":false,"given":"Achim","family":"Rieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e8ce","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Pellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lebioda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.10.002_bib1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.10.002_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-018-3546-8","article-title":"Navigating the treatment landscape in multiple myeloma: which combinations to use and when?","volume":"98","author":"Goldschmidt","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.10.002_bib3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.002_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CLM.2005.n.045","article-title":"New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals","volume":"6","author":"Durie","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2020.10.002_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SPC.0b013e328342f9cc","article-title":"Chemotherapy-induced neuropathic pain","volume":"5","author":"Farquhar-Smith","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.clml.2020.10.002_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2020.10.002_bib7","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2020.10.002_bib8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.10.002_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.mayocp.2015.05.004","article-title":"Peripheral neuropathy: a practical approach to diagnosis and symptom management","volume":"90","author":"Watson","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2020.10.002_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.10.002_bib11","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.6004\/jnccn.2010.0115","article-title":"Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia","volume":"8","author":"Richardson","year":"2010","journal-title":"J\u00a0Natl. Compr Canc Netw"},{"key":"10.1016\/j.clml.2020.10.002_bib12","first-page":"1431","article-title":"Treatment-related symptom management in patients with multiple myeloma: a review","volume":"23","author":"Colson","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2020.10.002_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.10.002_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.10.002_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/17474086.2015.1021772","article-title":"Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations","volume":"8","author":"Maes","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2020.10.002_bib16","first-page":"29","article-title":"Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States","volume":"24","author":"Carlson","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2020.10.002_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13561-019-0251-9","article-title":"Patient-reported data informing early benefit assessment of rare diseases in Germany: a systematic review","volume":"9","author":"Babac","year":"2019","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.clml.2020.10.002_bib18","doi-asserted-by":"crossref","first-page":"A483","DOI":"10.1016\/j.jval.2016.09.787","article-title":"The value of patient reported outcomes in German Amnog dossiers","volume":"19","author":"Borchert","year":"2016","journal-title":"Value in Health"},{"key":"10.1016\/j.clml.2020.10.002_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11136-019-02307-5","article-title":"Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed\/refractory multiple myeloma, based on German benefit assessment data","volume":"29","author":"Weisel","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2020.10.002_bib20","unstructured":"Gemeinsamer Bundesausschuss (G-BA). The benefit assessment of medicinal products in accordance with the German Social Code, Book Five (SGB V), section 35a. Vol 20202011. Available at: https:\/\/www.g-ba.de\/english\/benefitassessment\/. Accessed November 12, 2020."},{"key":"10.1016\/j.clml.2020.10.002_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2020.10.002_bib22","series-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.clml.2020.10.002_bib23","series-title":"EORTC QLQ-C30 reference values","author":"Scott","year":"2008"},{"key":"10.1016\/j.clml.2020.10.002_bib24","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.10.002_bib25","doi-asserted-by":"crossref","first-page":"842867","DOI":"10.1100\/2012\/842867","article-title":"Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma","volume":"2012","author":"Kontodimopoulos","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.clml.2020.10.002_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-8-79","article-title":"Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma","volume":"8","author":"Kvam","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clml.2020.10.002_bib27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3324\/haematol.2015.127860","article-title":"Health-related quality of life in patients with multiple myeloma--does it matter?","volume":"100","author":"Kvam","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.10.002_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13316","article-title":"Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients","volume":"103","author":"Sully","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.10.002_bib29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s11136-014-0853-y","article-title":"Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs","volume":"24","author":"Snyder","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2020.10.002_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","volume":"11","author":"Dimopoulos","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2020.10.002_bib31","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1182\/blood-2018-99-110957","article-title":"Association between patient profile and outcomes of best responders to carfilzomib: a post-hoc sub-group analysis of aspire and endeavor [abstract]","volume":"132","author":"Weisel","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.002_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1721.1721","article-title":"Psychometric performance of the EORTC quality-of-life core questionnaire (QLQ-C30) and QLQ-multiple myeloma (QLQ-MY20) in Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"122","author":"Leleu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.002_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the United States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.10.002_bib34","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Despiegel","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.10.002_bib35","series-title":"Impact of patients characteristics on health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the CHARISMMA study","author":"Rosi\u00f1ol","year":"2019"},{"key":"10.1016\/j.clml.2020.10.002_bib36","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00277-017-2991-0","article-title":"Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey","volume":"96","author":"Merz","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.10.002_bib37","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1080\/10428194.2018.1448084","article-title":"Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials","volume":"59","author":"Gengenbach","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.10.002_bib38","author":"Klepin"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030553X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030553X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:46Z","timestamp":1761871006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502030553X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S215226502030553X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.10.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}